BioCapTM NEUROD2 mRNA
Catalog Number: 1004201| SKU | Price | Buy |
|---|---|---|
| 1004201-500ug | $1,550.00 | |
| 1004201-1mg | $2,025.00 |
Description
NEUROD2 / BHLHA1 NDRF
SPECIES:
Human
ENCODED PROTEIN NAME:
Neurogenic differentiation factor 2
Function:
Transcriptional regulator implicated in neuronal determination. Mediates calcium-dependent transcription activation by binding to E box-containing promoter. Critical factor essential for the repression of the genetic program for neuronal differentiation; prevents the formation of synaptic vesicle clustering at active zone to the presynaptic membrane in postmitotic neurons. Induces transcription of ZEB1, which in turn represses neuronal differentiation by down-regulating REST expression. Plays a role in the establishment and maturation of thalamocortical connections; involved in the segregation of thalamic afferents into distinct barrel domains within layer VI of the somatosensory cortex. Involved in the development of the cerebellar and hippocampal granular neurons, neurons in the basolateral nucleus of amygdala and the hypothalamic-pituitary axis. Associates with chromatin to the DPYSL3 E box-containing promoter (By similarity). (Source: UniProt http://www.uniprot.org/uniprot/q15784)
Sequence (382 aa):
For the DNA coding sequence that is used as the template to synthesize the NEUROD2 mRNA mimetic, please contact us at customerservice@pharna.com.
For potential mRNA mimetics encoding splice variants or isoforms of your interest, please contact us at customerservice@pharna.com and it is our promise to fulfill your needs.
PhaRNA, LLC is looking for academic and industry collaborators and partners to co-develop RNA-based therapeutics including vaccines for the prevention or treatment of microbial diseases caused by parasites, fungi, viruses and bacteria. Our company’s proprietary technology has the versatility of rapidly designing RNA-based products for testing and development in preclinical and clinical settings. More specifically, we are looking for potential collaborators and partners who have the capacity to take our custom-designed RNA products and test their efficacy using molecular, cell biological and animal models. We will then partner to develop the most promising drug candidates through early phase clinical studies. We believe that this form of collaboration will capitalize on the strengths of PhaRNA, LLC and the partnering organization to rapidly test and develop potentially life-saving drugs and vaccines. Interested parties, please contact us directly.